Evaluating counseling outcome on adherence to prophylaxis and follow-up after sexual HIV-risk exposure: A randomized controlled trial

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 22, Issue 12, 2010, Pages 1509-1516

  Bentz, L ^a   Enel, P ^b   Dunais, B ^a   Durant, J ^a   Poizot Martin, I ^b   Tourette Turgis, C ^c   Rebillon, M ^c   Le Duff, F ^a   Dellamonica, P ^a   Pradier, C ^a  

^a UNIVERSITY HOSPITAL OF NICE   (France)

^b University Hospital of Marseille   (France)

^c UNIVERSITÉ DE ROUEN   (France)

Author keywords

adherence; counseling; HIV; non occupational post exposure prophylaxis; randomized controlled trial

Indexed keywords

DIDANOSINE; LAMIVUDINE; NELFINAVIR; ZIDOVUDINE;

ADULT; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NURSE; PATIENT COMPLIANCE; PATIENT COUNSELING; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; SEXUAL INTERCOURSE;

ADULT; ANTI-HIV AGENTS; COUNSELING; FEMALE; FRANCE; HIV INFECTIONS; HUMANS; MALE; PATIENT COMPLIANCE; POST-EXPOSURE PROPHYLAXIS; PROSPECTIVE STUDIES; RISK FACTORS; SEXUAL BEHAVIOR; TREATMENT OUTCOME;

EID: 78650279573     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540121.2010.484457     Document Type: Article

References (33)

1. Almeda, J., Casabona, J., Simon, B., Gerard, M., Rey, D., Puro, V., & Thomas, T. on behalf of the Euro- NONOPEP Project Group. (2004). Proposed recommendations for the management of HIV post-exposure prophylaxis after sexual, injecting drug or other exposures in Europe. Euro Surveillance, 9, 35-40.
2. Cardo, D.M., Culver, D.H., Ciesielski, C.A., Srivastava, P.U., Marcus, R., Abiteboul, D., . . . Bell, D.M. (1997). A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. New England Journal of Medicine, 337, 1542-1543.
3. Carrieri, P., & the APROCO cohort (2001). The dynamic of adherence to highly active antiretroviral therapy: Results from the French National APROCO cohort. Journal of Acquired Immune Deficiency Syndrome, 28, 232-239.
4. Center for Disease Control [CDC]. (2005). Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States. Recommendations from the U.S. Department of Health and Human Services. MMWR. Recommendations and Reports, 54(RR-2), 1-20. Retrieved from http://www.cdc.gov/mmwr/preview/ mmwrhtml/rr5402a1.htm
5. Center for Disease Control [CDC].(2006). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recommendations and Reports, 55(RR14, 1-17. Retrieved from http://www.cdc.gov/ mmwr/preview/mmwrhtml/rr5514a1.htm.
6. Center for Disease Control [CDC]. (2008). Recommendations for partner services programs for HIV infection, syphilis, gonorrhea, and chlamydial infection. MMWR Recommendations and Reports, 57(RR-9), 1-83; quiz CE1-4. Retrieved from http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5709a1.htm
7. Chesney, M.A. (2000). Factors affecting adherence to antiretroviral therapy. Clinical Infectious Diseases, 30(Suppl. 2), S171-S176.
8. Day, S., Mears, A., Bond, K., & Kulasegaram, R. (2006). Post-exposure HIV prophylaxis following sexual exposure: A retrospective audit against recent draft BASHH guidance. Sexually Transmitted Infections, 82, 236-237.
9. Deschamps, A.E., De Geest, S., Vandamme, A.M., Bobbaers, H., Peetermans, W.E., & Van Wijngaerden, E. (2008). Diagnostic value of different adherence measures using electronic monitoring and virologic failure as reference standards. AIDS Patient Care and STDS, 22, 735-743.
10. Duran, S., & the APROCO Cohort Study Group (2001). Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clinical Trials, 2, 38-45.
11. Fisher, J.D., Cornman, D.H., Norton, W.E., & Fisher, W.A. (2006). UK guideline for the use of postexposure prophylaxis for HIV following sexual exposure. International Journal of STD & AIDS, 17, 81-92.
12. Golub, S.A., Rosenthal, L., Cohen, D.E., & Mayer, K.H. (2008). Determinants of high-risk sexual behavior during post-exposure prophylaxis to prevent HIV infection. AIDS and Behavior, 12, 852-859.
13. Goujard, C., Bernard, N., Sohier, N., Peyramond, D., Lancon, F., Chwalow, J., . . . Delfraissy, J.F. (2003). Impact of a patient education program on adherence to HIV medication: A randomized clinical trial. Journal of Acquired Immune Deficiency Syndrome, 34, 191-194.
14. Kahn, J.O., Martin, J.N., Roland, M.E., Bamberger, J.D., Chesney, M., Chambers, D., . . . Katz, M.H. (2001). Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: The San Francisco PEP study. Journal of Infectious Diseases, 183, 707-714. (Pubitemid 32171744)
15. Knobel, H., Carmona, A., Lopez, J.L., Gimeno, J.L., Saballs, P., Gonzá lez, A., . . . D?́ez, A. (1999). Adherence to very active antiretroviral treatment: Impact of individualized assessment. Enfermedades Infecciosas y Microbiolog?́a Cl?́nica, 17, 78-81.
16. Lacombe, K., Daguenel-Nguyen, A., Lebeau, V., Fonquernie, L., Girard, P.M., & Meyohas, M.C. (2006). Determinants of adherence to non-occupational post HIV exposure prophylaxis. AIDS, 20, 291-294.
17. Laporte, A., Jourdan, N., Bouvet, E., Lamontagne, F., Pillonel, J., & Desenclos, J.C. (2002). Post-exposure prophylaxis after non-occupational HIV exposure: Impact of recommendations on physicians experiences and attitudes. AIDS, 16, 397-405.
18. Lot, F., Larsen, C., & Herida, M. (2007). Prophylaxie postexposition au VIH: Evaluation nationale et étude cout efficacité [HIV post-exposure prophylaxis: National evaluation and cost-effectiveness]. In Saint Maurice: Institut National de Veille Sanitaire (Eds.), Lutte contre le VIH/Sida et les infections sexuellement transmissibles en France-10 ans de surveillance, 1996-2005 [Ten years surveillance of HIV/AIDS and STI control in France, 1996-2005] (pp. 114-121). Saint Maurice: Institut de Veille Sanitaire. Retrieved from http://www.invs.sante.fr/publications/2007/10ans-vih
19. Luque, A., Hulse, S., Wang, D., Shahzad, U., Tanzman, E., Antenozzi, S., & Smith, B. (2007). Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and non occupational exposures to prevent transmission of human immunodeficiency virus. Infection Control and Hospital Epidemiology, 28, 695-701.
20. Mayer, K.H., Mimiaga, M.J., Cohen, D., Grasso, C., Bill, R., Van Derwarker, R., & Fisher, A. (2008). Tenofovir DFplus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center. Journal of Acquired Immune Deficiency Syndrome, 47, 494-499.
21. Miller, L.G., & Hays, R.D. (2000). Adherence to combination antiretroviral therapy: Synthesis of the literature and clinical implications. AIDS Reader, 10, 177-185.
22. Miller, W.R., Zweben, A., DiClemente, C.C., & Rychtarik, R. (1992). Motivational enhancement therapy manual: A clinical research guide for therapists treating individuals with alcohol abuse and dependence (283 p.). Rockville, MD: National Institute on Alcohol Abuse and Alcoholism.
23. Moher, D., Schulz, K.F., & Altman, D.G. (2001). The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet, 357, 1191-1194. (Pubitemid 32378696)
24. Moore, D.M., Hogg, R.S., Yip, B., Wood, E., Harris, M., & Montaner, J.S. (2006). Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy. HIV Medicine, 7, 311-316.
25. Pinkerton, S.D., Martin, J.N., Roland, M.E., Katz, M.H., Coates, T.J., & Kahn, J.O. (2004). Cost-effectiveness of postexposure prophylaxis after sexual or injectiondrug exposure to human immunodeficiency virus. Archives of Internal Medicine, 164, 46-54.
26. Pradier, C., Bentz, L., Spire, B., Tourette-Turgis, C., Morin, M., Souville, M., . . . Moatti, J.P. (2003). Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study. HIV Clinical Trials, 4, 121-131.
27. Rey, D., Bendiane, M.K., Bouhnik, A.D., Almeda, J., Moatti, J.P., & Carrieri, M.P. (2008). Physicians and patients adherence to antiretroviral prophylaxis after sexual exposure to HIV: Results from South-Eastern France. AIDS Care, 20, 537-541.
28. Roland, M.E. (2007). Postexposure prophylaxis after sexual exposure to HIV. Current Opinion in Infectious Diseases, 20, 39-46.
29. Simoni, J.M., Pearson, C.R., Pantalone, D.W., Marks, G., & Crepaz, N. (2006). Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. Journal of Acquired Immune Deficiency Syndrome, 43(Suppl. 1), S23-S35.
30. Sonder, G.J., van den Hoek, A., Regez, R.M., Brinkman, K., Prins, J.M., Mulder, J.W., . . . Coutinho, R.A. (2007). Trends in HIV postexposure prophylaxis prescription and compliance after sexual exposure in Amsterdam, 2000-2004. Sexually Transmitted Diseases, 34, 288-293.
31. Stephenson, J., & Imrie, J. (1998). Why do we need randomised controlled trials to assess behavioural interventions? BMJ, 316, 611-613.
32. Tuldra, A., Fumaz, C.R., Ferrer, M.J., Bayes, R., Arno, A., Balague, M., . . . Clotet, B. (2000). Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve longterm adherence to highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndrome, 25, 221-228.
33. Yeni, P. (2006). Groupe dexperts, sous la direction de. Prise en charge des situations dexposition au risqué viral [Expert Group, under the supervision of. Management of viral risk exposure]. In Secré tariat dEtat àla Santé (Eds.), Prise en charge médicale des personnes infectées par le VIH. Recommandations du groupe dexperts [Medical management of HIV-infected persons. Expert recommendations] (pp. 302-317). Paris: Médecine-Sciences Flammarion.